NextSense — Non-Invasive Consumer EEG · fobi

NextSense

Develops in-ear EEG biosensors for continuous brain activity monitoring in wearable form-factors. Raised seed funding in 2020. Early-stage with prototypes in development. Focus on medical and wellness applications for continuous EEG.

Pioneering the ear-worn EEG category, which offers better comfort and compliance for long-term monitoring compared to headbands or caps, with potential for sleep and seizure tracking.

nextsense.ai Non-Invasive Consumer EEG

Australiaprivate

At a glance

Total raised

$21.3M

last round series a

Headcount

11-50

approximate · public range

Headquarters

Melbourne

Australia

Founded

2018

8 years active

Status

Private

Non-Invasive Consumer EEG

Subsector

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Already subscribed? Sign in →

Date	Stage	Amount	Valuation	Lead investors
Nov 11, 2025	Series A	$16M	—	Ascension Ventures
Jan 1, 2022	Seed	$5.3M	—	—

AI bull / bear

Bull case

NextSense owns a differentiated hardware thesis: the ear canal as a stable, low-motion-artifact site for continuous EEG. Headbands slip; caps are clinical-only. In-ear placement solves compliance for overnight seizure detection and sleep staging, two of the highest-value applications in neurology. If the prototype delivers signal quality comparable to scalp electrodes, NextSense leapfrogs every consumer EEG form factor on the market. The company also avoids the trap of chasing vague "wellness" metrics. By targeting medical-grade seizure and sleep monitoring out of the gate, it aligns with FDA-reimbursable use cases and payer-relevant endpoints. That regulatory path, while slow, creates a moat: competitors building ear-EEG for meditation scores will not clear 510(k). Early seed backing in 2020 signals that specialist investors saw the asymmetry. If NextSense hits its clinical validation milestones, it becomes the only M&A target for epilepsy and sleep portfolios that need a wearables channel.

Bear case

NextSense has not disclosed any funding beyond a seed round in 2020 — a five-year gap that suggests the prototype either failed technical validation or could not attract follow-on capital. In-ear EEG faces a fundamental physics problem: the ear canal's cartilaginous walls and limited electrode spacing reduce signal amplitude and spatial resolution versus scalp arrays. No published studies yet show the device can reliably detect interictal epileptiform discharges or stage sleep with clinically acceptable accuracy. Meanwhile, incumbents are not standing still. Muse and Dreem have existing cleared products and distribution; Apple has filed ear-EEG patents that could absorb the thesis at scale. Without disclosed revenue, partnerships, or a Series A, NextSense appears pre-revenue and pre-product — sitting in a dead zone where seed investors have moved on and crossover funds will not engage until FDA data exists. The longer the silence, the more likely the category stays theoretical.

Generated by deepseek-v4-flash · June 2, 2026Refreshes quarterly · see disclosures

NextSense

At a glance

Subscribe to see the full profile

Funding history

How they make money

Founder backgrounds

Jonathan Berent

AI bull / bear

In the news

Leadership

Products

Smartbuds

Compare NextSense with